PCYC

Pharmacyclics, Inc. Press Releases

$140.33
*  
1.81
1.31%
Get PCYC Alerts
*Delayed - data as of Nov. 21, 2014  -  Find a broker to begin trading PCYC now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By
IMBRUVICA® (ibrutinib) Data to be Presented Across Multiple Histologies, Including in Eight Oral Presentations, at 2014 American Society of Hematology (ASH) Annual Meeting
11/6/2014 9:09:00 AM - PR Newswire
▲6.31 % Price Change since this news event. The Volume Ratio is 1.31.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Keith Lui Joins Versartis to Lead Global Marketing Efforts
11/6/2014 8:30:00 AM - GlobeNewswire


Pharmacyclics Reports Third Quarter 2014 Financial Results and Provides Clinical Program Update
11/4/2014 4:05:00 PM - PR Newswire
▲7.12 % Price Change since this news event. The Volume Ratio is 1.31.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


AstraZeneca And Pharmacyclics Enter Clinical Trial Collaboration To Evaluate IMBRUVICA® In Hematologic Cancers
11/4/2014 2:32:00 PM - PR Newswire
▲7.15 % Price Change since this news event. The Volume Ratio is 1.01.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


AstraZeneca And Pharmacyclics Enter Immuno-Oncology Clinical Trial Collaboration With IMBRUVICA® In Solid Tumors
11/4/2014 11:00:00 AM - PR Newswire
▲7.76 % Price Change since this news event. The Volume Ratio is 0.73.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


AstraZeneca, Pharmacyclics And Janssen Partner On Immuno-Oncology Combination Trials With IMBRUVICA® For Hematologic Cancers
11/4/2014 8:00:00 AM - PR Newswire
▲8.03 % Price Change since this news event. The Volume Ratio is 0.76.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Cochlear Pleased CMS Will Continue Coverage Of Baha® System For Medicare Patients Needing This Hearing Technology
11/4/2014 8:00:00 AM - PR Newswire


Pharmacyclics Announces Conference Call to Discuss Third Quarter Financial Results
10/28/2014 6:11:00 PM - PR Newswire
▲7.24 % Price Change since this news event. The Volume Ratio is 0.97.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


IMBRUVICA® (ibrutinib) Supplemental New Drug Application Submitted to the U.S. FDA for Waldenstrom's macroglobulinemia
10/20/2014 8:05:00 AM - PR Newswire


Pharmacyclics Files Supplemental New Drug Application for IMBRUVICA® for Waldenstrom''s Macroglobulinemia
10/20/2014 8:00:00 AM - PR Newswire
▲24.96 % Price Change since this news event. The Volume Ratio is 0.81.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


IMBRUVICA® (ibrutinib) Now Approved in Europe for Treatment of Two Blood Cancers
10/17/2014 8:49:00 AM - PR Newswire
▲28.58 % Price Change since this news event. The Volume Ratio is 1.32.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Pharmacyclics Enters Into Agreement with Roche to Evaluate IMBRUVICA® and GAZYVA® in Lymphoma and Leukemia
10/16/2014 2:45:00 PM - PR Newswire
▲26.82 % Price Change since this news event. The Volume Ratio is 0.66.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Bristol-Myers Squibb, Pharmacyclics and Janssen Announce Clinical Collaboration to Evaluate OPDIVO® (nivolumab) and IMBRUVICA®(ibrutinib) in Non-Hodgkin Lymphoma
10/13/2014 8:00:00 AM - Business Wire
▲32.42 % Price Change since this news event. The Volume Ratio is 1.23.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Pharmacyclics and Servier Agree to Conclude Pan-HDAC Inhibitor Collaboration
9/25/2014 4:01:00 PM - PR Newswire